Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
Upturn AI SWOT - About
Fidelity Disruptive Medicine ETF (FMED)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/13/2025: FMED (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type ETF | Historic Profit 17.84% | Avg. Invested days 60 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | ETF Returns Performance  3.0 |
| Profits based on simulation | Last Close 11/13/2025 |
Key Highlights
Volume (30-day avg) - | Beta 0.83 | 52 Weeks Range 20.69 - 26.79 | Updated Date 06/30/2025 |
52 Weeks Range 20.69 - 26.79 | Updated Date 06/30/2025 |
Upturn AI SWOT
Fidelity Disruptive Medicine ETF
ETF Overview
Overview
Fidelity Disruptive Medicine ETF (FMED) focuses on investing in companies involved in disruptive technologies and advancements within the healthcare sector, including genomics, personalized medicine, and digital health.
Reputation and Reliability
Fidelity is a well-established and reputable financial services company with a long history of managing investment funds.
Management Expertise
Fidelity has a team of experienced investment professionals dedicated to analyzing and selecting companies in the disruptive medicine space.
Investment Objective
Goal
To provide investment results that correspond to the performance of companies engaged in disruptive medicine.
Investment Approach and Strategy
Strategy: FMED invests in companies believed to benefit from advancements in medicine and healthcare technologies.
Composition The ETF primarily holds stocks of companies involved in areas like genetic sequencing, targeted therapies, and healthcare technology.
Market Position
Market Share: Data unavailable on specific FMED market share in the specific 'Disruptive Medicine' ETF category since it is not a precisely defined sector. Instead, a proxy of Biotech and Healthcare innovation ETFs is used.
Total Net Assets (AUM): 107500000
Competitors
Key Competitors
- ARK Genomic Revolution ETF (ARKG)
- Global X Genomics & Biotechnology ETF (GNOM)
- iShares Biotechnology ETF (IBB)
- SPDR S&P Biotech ETF (XBI)
Competitive Landscape
The disruptive medicine ETF space is competitive, with larger players like ARKG dominating. FMED benefits from Fidelity's brand and research capabilities. Compared to broad Biotech ETFs such as IBB and XBI, FMED is concentrated on the 'disruptive' themes within medicine. The advantage is higher growth potential; the disadvantage is higher volatility.
Financial Performance
Historical Performance: Historical performance data for FMED over various time periods (e.g., 1-year, 3-year, 5-year) needs to be retrieved from financial data providers.
Benchmark Comparison: Comparing FMED's performance to a broad healthcare or biotechnology index (e.g., IBB or IXJ) helps assess its added value.
Expense Ratio: 0.39
Liquidity
Average Trading Volume
The ETF's liquidity is moderate, evidenced by an average daily trading volume generally above 50,000 shares.
Bid-Ask Spread
FMED typically maintains a tight bid-ask spread, which implies relatively low transaction costs.
Market Dynamics
Market Environment Factors
Economic indicators, regulatory changes in healthcare, technological advancements in medicine, and investor sentiment towards innovation influence FMED.
Growth Trajectory
FMEDu2019s growth is tied to the adoption and commercial success of disruptive medical technologies and the healthcare sector's overall performance.
Moat and Competitive Advantages
Competitive Edge
FMED leverages Fidelity's extensive research capabilities and established platform. Fidelity's brand recognition and distribution network provide an advantage. The ETF's focused approach on disruptive medicine allows for targeted exposure to high-growth areas. The selection process by the Fidelity management team is also an advantage. However, niche focus exposes the portfolio to greater volatility.
Risk Analysis
Volatility
FMED experiences moderate to high volatility due to its focus on growth-oriented companies in the disruptive medicine sector.
Market Risk
The ETF is exposed to market risk, sector-specific risks (healthcare and biotechnology), and the risk of technological obsolescence within the disruptive medicine field.
Investor Profile
Ideal Investor Profile
Investors with a long-term investment horizon and a high risk tolerance are well-suited for FMED. Those who believe in the potential of disruptive medical technologies.
Market Risk
FMED is suited for long-term investors seeking growth potential within the healthcare sector, understanding its inherent risks.
Summary
The Fidelity Disruptive Medicine ETF (FMED) offers exposure to innovative companies in the healthcare sector. With Fidelity's management and a focus on emerging technologies, it presents a growth opportunity. However, its concentration on disruptive medicine entails higher volatility. Ideal investors are those with long-term goals and a tolerance for risk. FMED can be considered a thematic ETF within a diversified portfolio for exposure to cutting-edge healthcare advancements.
Similar ETFs
Sources and Disclaimers
Data Sources:
- Fidelity Investments website
- ETF.com
- Bloomberg
- Yahoo Finance
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be made based on individual circumstances and consultation with a qualified financial advisor. Data is based on available information and may be subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Fidelity Disruptive Medicine ETF
Exchange NASDAQ | Headquaters - | ||
IPO Launch date - | CEO - | ||
Sector - | Industry - | Full time employees - | Website |
Full time employees - | Website | ||
The fund normally invests at least 80% of assets in securities of disruptive medicine companies. Fidelity's disruptive strategies seek to identify innovative developments that could signal new directions for delivering products and services to customers. Generally, these companies have or are developing new or unconventional ways of doing business that could disrupt and displace incumbents over time. The fund is non-diversified.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.